**SUNDAY, MARCH 21**
Arrival and Registration

**MONDAY, MARCH 22**

**Welcome and Keynote Session (Joint)**
- **Helen H. Hobbs**, University of Texas Southwestern Medical Center, USA
  - PNPLA3's Role in NAFLD
- **Hashem B. El-Serag**, Baylor College of Medicine, USA
  - Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers

**Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint)**
- **Lopa Mishra**, George Washington University, USA
  - TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma
- Speaker to be Announced

**Short Talks Chosen from Abstracts**
- Genetics of NAFLD (X5)
  - **Elizabeth K. Speliotes**, University of Michigan, USA
    - Use of GWAS to Identify SNPs Associated with NAFLD
  - **Hannele Yki-Järvinen**, University of Helsinki, Finland
    - Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism
  - **Noura S. Abul-Husn**, Icahn School of Medicine at Mount Sinai, USA
    - HSD17B13 and Protection from Liver Disease in Diverse Patient Populations
- Speaker to be Announced

**The Role of the Microbiome in Hepatobiliary Cancers (X6)**
- **Silvia Affo**, Columbia University, USA
  - The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers
- **Amaia Lujambio**, Icahn School of Medicine at Mount Sinai, USA
  - Mechanisms of Immune Escape in Hepatocellular Carcinoma
- **Gregory J. Gores**, Mayo Clinic, USA
  - Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
- Speaker to be Announced

**Short Talks Chosen from Abstracts**
- NAFLD and CVD (X5)
  - **Jay D. Horton**, University of Texas Southwestern Medical Center, USA
    - Molecular Mediators of NAFLD and Hyperlipidemia
  - **Henry N. Ginsberg**, Columbia University College of Physicians and Surgeons, USA
    - Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets
- Speaker to be Announced

**Hepatobiliary Cancer Biomarkers (X6)**
- **Yujin Hoshida**, UT Southwestern Medical Center, USA
  - Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts
- **Irene Oi Lin Ng**, University of Hong Kong, Hong Kong
  - Molecular Biomarkers in Hepatocellular Carcinoma

**TUESDAY, MARCH 23**

**Role of Lipids in NAFLD (X5)**
- **Mitchell A. Lazar**, Perelman School of Medicine, University of Pennsylvania, USA
  - Circadian Contributions to NAFLD
- **Daniel A. Heller**, Memorial Sloan Kettering Cancer Center, USA
  - Lipid Dysregulation in Inflammation, NASH, and Cancer
- **Cathearine Postic**, INSERM, Institut Cochin, France
  - Altered Insulin Signaling and Glucose Toxicity in NAFLD
- **Tobias C. Walther**, Harvard School of Public Health, USA
  - Lipid Droplet Biology in NAFLD

**Short Talks Chosen from Abstracts**
- **Tumor Microenvironment and Hepatobiliary Cancers (X6)**
  - **Silvia Affo**, Columbia University, USA
    - The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers
  - **Amaia Lujambio**, Icahn School of Medicine at Mount Sinai, USA
    - Mechanisms of Immune Escape in Hepatocellular Carcinoma
  - **Gregory J. Gores**, Mayo Clinic, USA
    - Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
- Speaker to be Announced

**Short Talks Chosen from Abstracts**
- **NAFLD and CVD (X5)**
  - **Jay D. Horton**, University of Texas Southwestern Medical Center, USA
    - Molecular Mediators of NAFLD and Hyperlipidemia
  - **Henry N. Ginsberg**, Columbia University College of Physicians and Surgeons, USA
    - Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets
- Speaker to be Announced

**Hepatobiliary Cancer Biomarkers (X6)**
- **Yujin Hoshida**, UT Southwestern Medical Center, USA
  - Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts
- **Irene Oi Lin Ng**, University of Hong Kong, Hong Kong
  - Molecular Biomarkers in Hepatocellular Carcinoma

* Session Chair † Invited but not yet accepted     Program current as of May 1, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit [https://www.keystonesymposia.org](https://www.keystonesymposia.org).
WEDNESDAY, MARCH 24
Pathways to NASH (X5)
Speaker to be Announced
Mark A. McNiven, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease
Eran Elinav, Weizmann Institute of Science, Israel
Lipid-Associated Macrophages Control Metabolic Homeostasis
Speaker to be Announced
Short Talks Chosen from Abstracts

Genomic and Epigenomic Heterogeneity in Hepatobiliary Cancers (X6)
Xin Wei Wang, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers
Jessica Zucman-Rossi, University Paris Descartes-HEGP, France
Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes
Renumathy Dhanasekaran, Stanford University, USA
Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma
Bin Tean Teh, Duke-NUS Medical School, Singapore
Cholangiocarcinoma in Diverse Populations
Short Talks Chosen from Abstracts

Emerging Therapies for NASH-I (X5)
Morris J. Birnbaum, Pfizer Inc., USA
DGAT2 Inhibition for NASH
Robert F. Schwabe, Columbia University, USA
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches
Short Talks Chosen from Abstracts

Emerging Therapies for NASH-II (X5)
Kendra K. Bence, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD
Chuhan Chung, Gilead Sciences, USA
ACC Inhibitors for NASH
Lei Ling, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis
Short Talks Chosen from Abstracts

THURSDAY, MARCH 25
Departure